Oxurion NV — Major Shareholding Notification 2025

Jul 30, 2025

PRESS RELEASE

Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – July 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on July 29, 2025, from Atlas Special Opportunities II, LLC indicating that as of July 21, 2025, it held 1,845,939 shares of the then outstanding 12,428,021 shares, and therefore crossed under the threshold (15%) by virtue of the selling of voting securities.

This press release replaces the press release published on July 23, 2025.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY		Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
ldentification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting secunties or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Atlas Special Opportunities II LLC		2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of votinq rights (only to be filled in if art. 7 of the Law applies)
	Name			Address (for legal entities)
B	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6			Part II
7) Date on which the threshold is crossed
			21/07/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
15
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		12,428,021
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights	Previous notification		After the transaction
	# of voting rights		# of voting rights	Not linked to the		% of voting rights Not linked to the
Holders of voting rights			Linked to securities	ecunties	Linked to securities

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL				O	0.00%
3	The totals will be updated once you have clicked on

TOTAL (A & B)			# of voting rights % of voting rights
	CALCULATE	1,845,939	14.85%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy votinq for only one GM

13) Additional information

17 - 4 25 - 4 ammer 4 - 1 - 2 - 2014 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -

	Done at New York
On		28/07/2025 (DD/MM/YYYY)
	Name & capacity Patrick Vance, Proxyholder

For security reasons, the unsigned form in xlsx format should
be transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the " Send" button.

In addition, a signed copy in PDF format should also be transmitted.